Edition:
United Kingdom

Glaukos Corp (GKOS.N)

GKOS.N on New York Stock Exchange

43.02USD
15 Jun 2018
Change (% chg)

$-0.77 (-1.76%)
Prev Close
$43.79
Open
$43.69
Day's High
$44.05
Day's Low
$42.32
Volume
158,793
Avg. Vol
118,513
52-wk High
$44.74
52-wk Low
$23.10

Chart for

About

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision... (more)

Overall

Beta: --
Market Cap(Mil.): $1,156.64
Shares Outstanding(Mil.): 34.43
Dividend: --
Yield (%): --

Financials

  GKOS.N Industry Sector
P/E (TTM): -- 32.19 32.75
EPS (TTM): -0.04 -- --
ROI: -0.98 13.89 14.38
ROE: -0.98 16.72 16.07

BRIEF-Glaukos Q1 Loss Per Share $0.08

* GLAUKOS CORP ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

BRIEF-Glaukos Q4 Earnings Per Share $0.03

* ORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

28 Feb 2018

BRIEF-Glaukos' Idose Travoprost Achieves Sustained IOP Reduction And Favorable Safety Profile In 12-Month Interim Cohort

* GLAUKOS CORPORATION’S IDOSE™ TRAVOPROST ACHIEVES SUSTAINED IOP REDUCTION AND FAVORABLE SAFETY PROFILE IN 12-MONTH INTERIM COHORT

10 Jan 2018

BRIEF-Glaukos Submits IDE Application To FDA To Study iStent Infinite Trabecular Micro-Bypass System

* GLAUKOS SUBMITS IDE APPLICATION TO FDA TO STUDY ISTENT INFINITE™ TRABECULAR MICRO-BYPASS SYSTEM

03 Jan 2018

Competitors

Earnings vs. Estimates